🏛️ Verified NIH Record • Updated 2025-05-16
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies (NCT04521413)
A First-In-Human, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Treadwell Therapeutics, Inc
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Who can join: Review the eligibility criteria below.
Location: University of California San Diego — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of California San Diego — La Jolla, California
- The Angeles Clinic — Los Angeles, California
- Yale Cancer Center — New Haven, Connecticut
- Florida Cancer Specialists — Sarasota, Florida
- START - Mid-West — Grand Rapids, Michigan
- SCRI - Nashville — Nashville, Tennessee
- MD Anderson — Houston, Texas
- START - San Antonio — San Antonio, Texas
- Virginia Cancer Specialist — Fairfax, Virginia
- Cross Cancer Institute — Edmonton, Alberta
- The Ottawa Hospital — Ottawa, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
- Prince of Wales Hospital — Shatin,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Malignancies
- Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) — Houston, Texas
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies — Baltimore, Maryland
- Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies — Los Angeles, California
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies — La Jolla, California
Explore by condition: All Advanced Solid Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.